|
1
|
Shields AF, Grierson JR, Dohmen BM, et al:
Imaging proliferation in vivo with [F-18]FLT and positron emission
tomography. Nat Med. 4:1334–1336. 1998.
|
|
2
|
Dittmann H, Dohmen BM, Kehlbach R, et al:
Early changes in [18F]FLT uptake after chemotherapy: an
experimental study. Eur J Nucl Med Mol Imaging. 29:1462–1469.
2002.
|
|
3
|
Kenny LM, Contractor KB, Stebbing J, et
al: Altered tissue 3′-deoxy-3′-[18F]fluorothymidine
pharmacokinetics in human breast cancer following capecitabine
treatment detected by positron emission tomography. Clin Cancer
Res. 15:6649–6657. 2009.
|
|
4
|
Pillai RG, Forster M, Perumal M, et al:
Imaging pharmacodynamics of the alpha-folate receptor-targeted
thymidylate synthase inhibitor BGC 945. Cancer Res. 68:3827–3834.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pressacco J, Wiley JS, Jamieson GP,
Erlichman C and Hedley DW: Modulation of the equilibrative
nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer.
72:939–942. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pressacco J, Mitrovski B, Erlichman C and
Hedley DW: Effects of thymidylate synthase inhibition on thymidine
kinase activity and nucleoside transporter expression. Cancer Res.
55:1505–1508. 1995.PubMed/NCBI
|
|
7
|
Lee SJ, Kim SY, Chung JH, Oh SJ, et al:
Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism
for 3′-deoxy-3′-[18F]fluorothymidine flare. Biochem Pharmacol.
80:1528–1536. 2010.PubMed/NCBI
|
|
8
|
Perumal M, Pillai RG, Barthel H, et al:
Redistribution of nucleoside transporters to the cell membrane
provides a novel approach for imaging thymidylate synthase
inhibition by positron emission tomography. Cancer Res.
66:8558–8564. 2006. View Article : Google Scholar
|
|
9
|
Cruet-Hennequart S, Villalan S,
Kaczmarczyk A, O’Meara E, Sokol AM and Carty MP: Characterization
of the effects of cisplatin and carboplatin on cell cycle
progression and DNA damage response activation in DNA polymerase
eta-deficient human cells. Cell Cycle. 8:3039–3050. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yau K, Price P, Pillai RG and Aboagye E:
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma
and HT29 colon adenocarcinoma cells after treatment with
thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging.
33:981–987. 2006. View Article : Google Scholar
|
|
11
|
Paproski RJ, Ng AM, Yao SY, Graham K,
Young JD and Cass CE: The role of human nucleoside transporters in
uptake of 3′-deoxy-3′-fluorothymidine. Mol Pharmacol. 74:1372–1380.
2008.
|
|
12
|
King AE, Ackley M, Cass CE, Young JD and
Baldwin SA: Nucleoside transporters: from scavengers to novel
therapeutic targets. Trends Pharmacol Sci. 27:416–425. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cass CE, Dahlig E, Lau EY, Lynch TP and
Paterson AR: Fluctuations in nucleoside uptake and binding of the
inhibitor of nucleoside transport, nitrobenzylthioinosine, during
the replication cycle of HeLa cells. Cancer Res. 39:1245–1252.
1979.PubMed/NCBI
|
|
14
|
Coe I, Zhang Y, McKenzie T and Naydenova
Z: PKC regulation of the human equilibrative nucleoside
transporter, hENT1. FEBS Lett. 517:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang M, Wang Y, Collins M, Gu JJ,
Mitchell BS and Graves LM: Inhibition of nucleoside transport by
p38 MAPK inhibitors. J Biol Chem. 277:28364–28367. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang M, Wang Y, Cogut SB, Mitchell BS and
Graves LM: Inhibition of nucleoside transport by protein kinase
inhibitors. J Pharmacol Exp Ther. 304:753–760. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grem JL, Danenberg KD, Behan K, et al:
Thymidine kinase, thymidylate synthase, and dihydropyrimidine
dehydrogenase profiles of cell lines of the National Cancer
Institute’s Anticancer Drug Screen. Clin Cancer Res. 7:999–1009.
2001.PubMed/NCBI
|
|
18
|
Lu X, Gong S, Monks A, Zaharevitz D and
Moscow JA: Correlation of nucleoside and nucleobase transporter
gene expression with antimetabolite drug cytotoxicity. J Exp Ther
Oncol. 2:200–212. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang JH, Chung TD and Oldenburg KR: A
simple statistical parameter for use in evaluation and validation
of high throughput screening assays. J Biomol Screen. 4:67–73.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Plotnik DA, McLaughlin LJ, Krohn KA and
Schwartz JL: The effects of 5-fluoruracil treatment on
3′-fluoro-3′-deoxythymidine (FLT) transport and metabolism in
proliferating and non-proliferating cultures of human tumor cells.
Nucl Med Biol. May 4–2012.(Epub ahead of print).
|
|
21
|
Liu L, Choi JH, Yim H, Choi JS, Park BD,
Cho SJ and Lee SK: ATR (AT mutated Rad3 related) activity
stabilizes Cdc6 and delays G2/M-phase entry during
hydroxyurea-induced S-phase arrest of HeLa cells. Int J Biochem
Cell Biol. 41:1410–1420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu S, Xie Y, Lv Y, et al: A novel target
of mizoribine inhibiting mesangial cell proliferation: S phase
kinase-associated protein 2. Am J Nephrol. 32:447–455. 2010.
View Article : Google Scholar : PubMed/NCBI
|
